Biotech | May 10, 2022
Bora Pharmaceuticals acquires Eden Biologics CDMO assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction is expected to close in the first quarter of 2022
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated
